The Global Gene Therapy Partnering Agreements 2014-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in gene therapy partnering deals Disclosed headlines, upfronts, milestones and royalties by stage of development Gene therapypartnering contract documents Top gene therapy deals by value
The Global Gene Therapy Partnering Terms and Agreements 2014-2020 report provides an understanding and access to the gene therapy partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter gene therapypartnering deals. The majority of deals are early development stage whereby the licensee obtains a right or an option right to license the licensors gene therapytechnology or product candidates. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest gene therapy, oligonucletides including aptamers agreements announced in the healthcare sectors.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of all gene therapy partnering deals announced since 2014 including financial terms where available including over 340 links to online deal records of actual gene therapy partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
For example, analyzing actual company deals and agreements allows assessment of the following: • What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What are the precise rights granted or optioned?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?
The initial chapters of this report provide an orientation of Gene therapy dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Gene therapy dealmaking since 2014, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading Gene therapy deals since 2014. Deals are listed by headline value, signed by big pharma, most active Gene therapy dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in Gene therapy dealmaking with a brief summary followed by a comprehensive listing of Gene therapy deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of Gene therapy partnering deals signed and announced since Jan 2014, where a contract document is available in the public domain. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of Gene therapy partnering deals signed and announced since Jan 2014. The chapter is organized by specific Gene therapy technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by Gene therapy partnering company A-Z, deal type definitions and Gene therapy partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in Gene therapy partnering and dealmaking since 2014.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Gene therapy technologies and products.
Report scope Global Gene Therapy Partnering Terms and Agreements is intended to provide the reader with an in-depth understanding and access to gene therapy trends and structure of deals entered into by leading companies worldwide.
Global Gene Therapy Partnering Terms and Agreements includes: Trends in gene therapy dealmaking in the biopharma industry since 2014 Analysis of gene therapy deal structure Access to headline, upfront, milestone and royalty data Case studies of real-life gene therapy deals Access to over 340 gene therapy deals The leading gene therapy deals by value since 2014 Most active gene therapy dealmakers since 2014 The leading gene therapy partnering resources
In Global Gene Therapy Partnering Terms and Agreements, the available contracts are listed by: Company A-Z Headline value Stage of development at signing Deal component type Specific therapy and technology target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Our reports have been used by over 10K customers, including:
Hepatocyte Growth Factor - Pipeline Review, H1 2020 Summary Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules. The latest report Hepatocyte Growth Factor - Pipeline Review, H1 2020, outlays comprehensive information on the Hepatocyte...
Gene Therapy Market Research Report by Type (Antigen Gene Therapy, Cancer Gene Therapy, Cytokine Gene Therapy, Suicide Gene Therapy, and Tumor Suppressor Gene Therapy), by Vector Type (Non-viral Vectors and Viral Vectors), by Application - Global Forecast to 2025 - Cumulative Impact of COVID-19 The Global Gene Therapy...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global Cell and Gene Therapy Market Report The global cell and gene therapy market by revenue is expected to grow at a CAGR of over 30.90% during the period 2019–2025. The global cell and gene therapy market is one of the fastest-growing segments...
Non Receptor Tyrosine Protein Kinase TYK2 - Pipeline Review, H1 2020 Summary Non Receptor Tyrosine Protein Kinase TYK2 (TYK2 or EC 18.104.22.168) – Non-receptor tyrosine-protein kinase TYK2 is an enzyme encoded by the TYK2 gene. It is involved in intracellular signal transduction by involving in the initiation...
This research identifies some the key developments across CAR-T cell therapies and provides insights across technological, IP, and investment landscapes. The study also provides an analysis of the competitive landscape while highlighting the key growth opportunities within the CAR-T cell therapy platform.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.